Analyst Ratings For NASDAQ:ARWR – Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Today, Cantor Fitzgerald reiterated its Buy rating on NASDAQ:ARWR – Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a price target of $13.00.
Some recent analyst ratings include
- 5/30/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 3/27/2018-Jefferies Group initiated coverage with a Buy rating.
- 2/19/2018-Chardan Capital Reiterated Rating of Buy.
- 9/18/2017-William Blair Upgrade from a “Market Perform ➝ Outperform” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:ARWR – Arrowhead Pharmaceuticals (NASDAQ:ARWR)
NASDAQ:ARWR – Arrowhead Pharmaceuticals (NASDAQ:ARWR) has insider ownership of 4.60% and institutional ownership of 44.58%.
- On 4/24/2018 Douglas B. Given, Director, sold 25,000 with an average share price of $6.63 per share and the total transaction amounting to $165,750.00.
- On 3/27/2018 Kenneth Allen Myszkowski, CFO, sold 20,000 with an average share price of $8.00 per share and the total transaction amounting to $160,000.00.
- On 3/15/2018 Christopher Richard Anzalone, CEO, sold 300,000 with an average share price of $7.43 per share and the total transaction amounting to $2,229,000.00.
- On 3/13/2018 Christopher Richard Anzalone, CEO, sold 100,000 with an average share price of $7.43 per share and the total transaction amounting to $743,000.00.
- On 3/5/2018 Bruce D Given, COO, sold 20,000 with an average share price of $6.73 per share and the total transaction amounting to $134,600.00.
- On 1/1/2018 Bruce D Given, COO, sold 20,000 with an average share price of $3.69 per share and the total transaction amounting to $73,800.00.
- On 10/14/2016 Douglas B. Given, Director, sold 12,000 with an average share price of $6.72 per share and the total transaction amounting to $80,640.00.
Recent Trading Activity for NASDAQ:ARWR – Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Shares of NASDAQ:ARWR – Arrowhead Pharmaceuticals closed the previous trading session at 10.87 up +0.57 5.53% with shares trading hands.